Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 5,348 matching trials from the live ClinicalTrials.gov search.
Filters: Milwaukee, Wisconsin Clear all
Completed Phase 2 Interventional Results available

A Study of TAK-079 in People With Generalized Myasthenia Gravis

NCT04159805
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
TAK-079, TAK-079 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
27
States / cities
Tucson, Arizona • Palo Alto, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 21, 2026, 4:02 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Transcranial Alternating Current Stimulation (tACS) in Aphasia

NCT04375722
View directory record Official record
Conditions
Aphasia, Stroke
Interventions
tACS
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 21, 2026, 4:02 PM EDT
Approved For Marketing No phase listed Expanded access

The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

NCT00354627
View directory record Official record
Conditions
HIV-1
Interventions
TMC125
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
182
States / cities
Anniston, Alabama • Birmingham, Alabama • Flagstaff, Arizona + 179 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 21, 2026, 4:02 PM EDT
Completed No phase listed Observational

Prospective Clinical Evaluation of the FilmArray® Lower Respiratory Tract Infection (LRTI) Panel

NCT03361670
View directory record Official record
Conditions
Lower Resp Tract Infection
Interventions
Observational Study
Other
Lead sponsor
BioFire Diagnostics, LLC
Industry
Eligibility
Not listed
Enrollment
1,689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Los Angeles, California • Maywood, Illinois • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 21, 2026, 4:02 PM EDT
Active, not recruiting Phase 2 Interventional

Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

NCT06109441
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ALTB-268
Biological
Lead sponsor
AltruBio Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
23
States / cities
San Diego, California • Littleton, Colorado • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 21, 2026, 4:02 PM EDT
Completed No phase listed Observational

The Financial Impact of Allogeneic Stem Cell Transplantation on Patient and Family

NCT00795054
View directory record Official record
Conditions
Financial Impact of Stem Cell Transplantation
Interventions
Household financial data collection
Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Minneapolis, Minnesota • Buffalo, New York • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 21, 2026, 4:02 PM EDT
Recruiting Not applicable Interventional

Blood Flow Regulation and Neuromuscular Function Post-Stroke

NCT06027294
View directory record Official record
Conditions
Stroke
Interventions
Ischemic Conditioning
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 21, 2026, 4:02 PM EDT
Completed Not applicable Interventional

Study of the Physical and Emotional Needs of Parents Caring for Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia

NCT00056069
View directory record Official record
Conditions
Leukemia
Interventions
questionnaire administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
107
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 21, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

NCT00968708
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Acute Coronary Syndrome
Interventions
Alogliptin, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
5,380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
292
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 289 more
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 21, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

NCT03526250
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
Interventions
Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 21, 2026, 4:02 PM EDT
Recruiting Phase 4 Interventional

Immune Modulation During Palynziq® Treatment in Adults (IMPALA)

NCT07477691
View directory record Official record
Conditions
Phenylketonuria
Interventions
Pegvaliase, Methotrexate
Biological · Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 21, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

NCT02345850
View directory record Official record
Conditions
Acute Leukemia, Myelodysplasia
Interventions
Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide, Cyclophosphamide, Tacrolimus, Methotrexate
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 65 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
28
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 21, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

NCT01372150
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
desvenlafaxine succinate sustained release, fluoxetine, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
41
States / cities
Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 21, 2026, 4:02 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

NCT05361174
View directory record Official record
Conditions
Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
IOV-4001
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 21, 2026, 4:02 PM EDT
Recruiting Phase 3 Interventional

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

NCT05848713
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Heparin
Drug
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Chicago, Illinois • Jefferson, Louisiana • Portland, Maine + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 4:02 PM EDT
Completed Not applicable Interventional Results available

Attain Stability™ Quad Clinical Study

NCT03099655
View directory record Official record
Conditions
Heart Failure
Interventions
Attain Stability Quad Left Ventricular Pacing Lead
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
35
States / cities
Phoenix, Arizona • East Palo Alto, California • Torrance, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 21, 2026, 4:02 PM EDT
Terminated Phase 3 Interventional Results available

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

NCT02663908
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Leuprolide
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
Male only
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
48
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 21, 2026, 4:02 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

NCT03210714
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Osteosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Refractory Childhood Malignant Germ Cell Tumor, Refractory Childhood Osteosarcoma, Refractory Childhood Rhabdomyosarcoma, Refractory Childhood Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Wilms Tumor
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Erdafitinib, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
114
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 4:02 PM EDT
Not listed Phase 2 Interventional

Study of the Safety and Efficacy of Zoenasa® Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

NCT01586533
View directory record Official record
Conditions
Ulcerative Colitis, Left-sided Ulcerative Colitis, Distal Ulcerative Colitis
Interventions
Zoenasa-1:4, Mesalamine Enema
Drug
Lead sponsor
Altheus Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
45
States / cities
Birmingham, Alabama • Dothan, Alabama • Lakewood, Colorado + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 21, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT01107626
View directory record Official record
Conditions
Lung Cancer
Interventions
Paclitaxel, Carboplatin, Bevacizumab, Pemetrexed Disodium Heptahydrate
Drug · Biological
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
434
States / cities
Anniston, Alabama • Fairbanks, Alaska • Fairfield, California + 312 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 21, 2026, 4:02 PM EDT
Terminated Phase 2 Interventional Results available

Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT

NCT02349178
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic, Acute Myeloid Leukemia
Interventions
Clofarabine, Cyclophosphamide, Etoposide
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 39 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Columbus, Ohio • Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 21, 2026, 4:02 PM EDT
Terminated Phase 3 Interventional Results available

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

NCT03199885
View directory record Official record
Conditions
Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma, Recurrent HER2-Positive Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Unresectable Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma
Interventions
Atezolizumab, Biopsy, Bone Scan, Computed Tomography, Docetaxel, Magnetic Resonance Imaging, Paclitaxel, Pertuzumab, Placebo Administration, Quality-of-Life Assessment, Trastuzumab
Drug · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
662
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 506 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 21, 2026, 4:02 PM EDT
Terminated Phase 2 Interventional

Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury

NCT02163876
View directory record Official record
Conditions
Cervical Spinal Cord Injury, Spine Injury, Cervical Spine Injury
Interventions
HuCNS-SC cells
Drug
Lead sponsor
StemCells, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Downey, California • Miami, Florida • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 21, 2026, 4:02 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes

NCT07228208
View directory record Official record
Conditions
Type 2 Diabetes (T2DM), Endothelial Dysfunction
Interventions
MitoQ (mitoquinol mesylate), Placebo
Dietary Supplement
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 21, 2026, 4:02 PM EDT